LUCD Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	300 346
Średni wolumen	222 227
Kapitalizacja rynkowa	46.28M
EPS	$-0.250 ( 2024-03-26 )
Następna data zysków	( $-0.270 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.740
ATR14	$0.00400 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-08	Matheis Dennis	Buy	241 500	Employee stock option (right to buy)
2024-05-06	Matheis Dennis	Sell	0	Common stock
2024-05-07	Gordon Michael Adam	Buy	400 000	Common stock
2024-05-07	O'neil Shaun	Buy	400 000	Common stock
2024-05-07	Mcgrath Dennis M	Buy	400 000	Common stock

INSIDER POWER
44.28
Last 63 transactions
Buy: 15 024 819 \| Sell: 4 158 892

Wolumen Korelacja

Długi: -0.02 (neutral)

Krótki: 0.23 (neutral)

Signal:(45.831) Neutral

Lucid Diagnostics Inc. Korelacja

10 Najbardziej pozytywne korelacje
HCDIP	0.958
NLSP	0.954
HAIN	0.951
SIRI	0.945
NOVN	0.943
TRVN	0.942
PHCF	0.941
RMGC	0.937
TTEC	0.937
FRHC	0.936

10 Najbardziej negatywne korelacje
TRMR	-0.96
VITL	-0.951
THRN	-0.941
ARTEU	-0.94
GGAL	-0.939
DXPE	-0.937
RZLT	-0.935
CDXC	-0.935
GHRS	-0.934
IXAQ	-0.932

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lucid Diagnostics Inc. Korelacja - Waluta/Towar

0.38
( neutral )

0.00
( neutral )

-0.27
( neutral )

Lucid Diagnostics Inc. Finanse

Annual	2023
Przychody:	$2.43M
Zysk brutto:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2023
Przychody:	$2.43M
Zysk brutto:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2022
Przychody:	$377 000
Zysk brutto:	$-3.24M (-858.62 %)
EPS:	$-1.550

FY	2021
Przychody:	$500 000
Zysk brutto:	$-85 000.00 (-17.00 %)
EPS:	$-1.510

Financial Reports:

No articles found.

Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Aktualne aktualizacje dla Lucid Diagnostics Inc. [LUCD]

Upcoming Earnings Alert